📊 ABEO Key Takeaways
Is Abeona Therapeutics Inc.. (ABEO) a Good Investment?
Abeona is a pre-commercial biotech burning cash at $19.8M annually with minimal revenue ($8.7M) and large operating losses despite showing revenue growth. While the strong balance sheet ($61.4M cash, 0.12x leverage) provides 3-4 years of runway, the fundamental lack of profitability, negative cash flow, and uncertain pipeline success warrant a cautious stance without clinical/regulatory catalysts.
Abeona Therapeutics shows strong balance-sheet liquidity and low leverage, which provides meaningful funding flexibility for a development-stage biotech. However, core fundamentals remain weak: revenue is still very small, operating losses are severe, and free cash flow is deeply negative, while the sharp swing to net income appears low quality relative to the underlying cash burn and operating performance. The company’s fundamental case depends more on improving commercialization and narrowing operating losses than on its current reported earnings.
Abeona Therapeutics Inc.. Key Strengths (ABEO)
- Strong liquidity position with $61.4M cash and 5.89x current ratio enabling extended R&D funding
- Conservative balance sheet with 0.12x debt-to-equity ratio minimizing financial distress risk
- Revenue growth of 66.3% YoY shows initial commercialization progress despite small base
- Very strong liquidity, with $78.44M in cash and a 6.93x current ratio
- Low financial leverage, with debt/equity of 0.13x and modest long-term debt relative to equity
- Revenue grew 66.3% year over year, indicating early top-line momentum
ABEO Stock Risks: Abeona Therapeutics Inc.. Investment Risks
- Severe cash burn of $19.8M annually in operating cash flow with only 3-4 year runway at current rate
- Deep unprofitability with -264.1% operating margin and -195.8% net margin indicating no viable business model yet
- Typical biotech execution risk: clinical trial failures, regulatory setbacks, or pipeline disappointments could require dilutive financing
- Operating margin of -1536.9% shows the business is far from self-sustaining
- Operating cash flow of -$76.33M and free cash flow of -$84.30M indicate heavy ongoing cash burn
- Net income quality is questionable because reported profitability is not supported by operating income or cash generation
Key Metrics to Watch
- Operating cash flow trend and burn rate reduction
- Revenue growth sustainability and path to gross profit
- Cash position and runway to profitability or next financing event
- Quarterly revenue growth and whether product revenue becomes more meaningful
- Operating cash burn and the pace of improvement in operating loss/free cash flow
Abeona Therapeutics Inc.. (ABEO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.89x current ratio provides a solid financial cushion.
ABEO Profit Margin, ROE & Profitability Analysis
ABEO vs Healthcare Sector: How Abeona Therapeutics Inc.. Compares
How Abeona Therapeutics Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Abeona Therapeutics Inc.. Stock Overvalued? ABEO Valuation Analysis 2026
Based on fundamental analysis, Abeona Therapeutics Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Abeona Therapeutics Inc.. Balance Sheet: ABEO Debt, Cash & Liquidity
ABEO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Abeona Therapeutics Inc..'s revenue has declined by 42% over the 5-year period, indicating business contraction. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
ABEO Revenue Growth, EPS Growth & YoY Performance
ABEO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.7M | -$12.0M | $-0.24 |
| Q3 2025 | $400.0K | -$5.2M | $-0.10 |
| Q2 2025 | $400.0K | $7.4M | $-0.26 |
| Q3 2024 | $3.5M | -$11.8M | $-0.48 |
| Q2 2024 | $3.5M | $7.4M | $-0.26 |
| Q3 2023 | $1.3M | -$6.4M | $-0.48 |
| Q2 2023 | $1.0M | -$4.1M | $0.92 |
| Q1 2023 | $346.0K | -$9.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Abeona Therapeutics Inc.. Dividends, Buybacks & Capital Allocation
ABEO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Abeona Therapeutics Inc.. (CIK: 0000318306)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABEO
What is the AI rating for ABEO?
Abeona Therapeutics Inc.. (ABEO) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABEO's key strengths?
Claude: Strong liquidity position with $61.4M cash and 5.89x current ratio enabling extended R&D funding. Conservative balance sheet with 0.12x debt-to-equity ratio minimizing financial distress risk. ChatGPT: Very strong liquidity, with $78.44M in cash and a 6.93x current ratio. Low financial leverage, with debt/equity of 0.13x and modest long-term debt relative to equity.
What are the risks of investing in ABEO?
Claude: Severe cash burn of $19.8M annually in operating cash flow with only 3-4 year runway at current rate. Deep unprofitability with -264.1% operating margin and -195.8% net margin indicating no viable business model yet. ChatGPT: Operating margin of -1536.9% shows the business is far from self-sustaining. Operating cash flow of -$76.33M and free cash flow of -$84.30M indicate heavy ongoing cash burn.
What is ABEO's revenue and growth?
Abeona Therapeutics Inc.. reported revenue of $8.7M.
Does ABEO pay dividends?
Abeona Therapeutics Inc.. does not currently pay dividends.
Where can I find ABEO SEC filings?
Official SEC filings for Abeona Therapeutics Inc.. (CIK: 0000318306) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABEO's EPS?
Abeona Therapeutics Inc.. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ABEO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Abeona Therapeutics Inc.. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ABEO stock overvalued or undervalued?
Valuation metrics for ABEO: ROE of -11.8% (sector avg: 15%), net margin of -195.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ABEO's AI grade for 2026?
Our dual AI analysis gives Abeona Therapeutics Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABEO's free cash flow?
Abeona Therapeutics Inc..'s operating cash flow is $-19.8M, with capital expenditures of $935.0K. FCF margin is -237.8%.
How does ABEO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -195.8% (avg: 12%), ROE -11.8% (avg: 15%), current ratio 5.89 (avg: 2).